Compare Nomura Holdings Inc (NMR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Novavax Inc — how do they compare? Nomura Holdings Inc trades at $9.49 (market cap $27.55B), while Novavax Inc trades at $11.1 (market cap $1.82B). The key difference: Nomura Holdings Inc is far larger — about 15.1× Novavax Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nomura Holdings Inc for 55 Days and Novavax Inc for 59 Days on average.
| NMR | NVAX | |
|---|---|---|
Market Cap | $27.55B | $1.82B |
Volume | 782,470 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $10.86 | $12.56 |
52-Week Low | $6.73 | $6.22 |
Typical Hold Time | 55 Days | 59 Days |
Enterprise Value | $38.54T | $1.39B |
Dividend Yield | 3.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.29 and P/B of 1.15. Analyst consensus leans cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
NMR presents a value opportunity with attractive valuation multiples, though execution risks persist. The bearish technical trend and inconsistent earnings performance warrant caution. Upside potential exists if the company can sustain revenue growth and improve cash flow generation, but investors should monitor debt levels increasing to 26.25% of assets.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
